Vir Biotechnology Inc [VIR] stock is trading at $5.93, up 11.89%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VIR shares have gain 16.05% over the last week, with a monthly amount glided 8.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vir Biotechnology Inc [NASDAQ: VIR] stock has seen the most recent analyst activity on January 29, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $9 from $23. Previously, BofA Securities downgraded its rating to Neutral on September 08, 2023, and dropped its price target to $14. On March 06, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $34 on the stock. Goldman upgraded its rating to a Buy and increased its price target to $53 on February 21, 2023. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $30 on January 27, 2023. SVB Leerink started tracking with a Outperform rating for this stock on September 14, 2022, and assigned it a price target of $40. In a note dated September 09, 2022, Morgan Stanley initiated an Underweight rating and provided a target price of $15 on this stock.
Vir Biotechnology Inc [VIR] stock has fluctuated between $4.32 and $14.45 over the past year. Currently, Wall Street analysts expect the stock to reach $27.85 within the next 12 months. Vir Biotechnology Inc [NASDAQ: VIR] shares were valued at $5.93 at the most recent close of the market. An investor can expect a potential return of 369.65% based on the average VIR price forecast.
Analyzing the VIR fundamentals
Vir Biotechnology Inc [NASDAQ:VIR] reported sales of 20.86M for the trailing twelve months, which represents a drop of -94.62%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -30.81%, Pretax Profit Margin comes in at -29.51%, and Net Profit Margin reading is -29.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.47 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.56 points at the first support level, and at 5.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.13, and for the 2nd resistance point, it is at 6.32.
Ratios To Look Out For
For context, Vir Biotechnology Inc’s Current Ratio is 6.79. In addition, the Quick Ratio stands at 6.79 and the Cash Ratio stands at 1.99. Considering the valuation of this stock, the price to sales ratio is 39.30, the price to book ratio is 0.78.
Transactions by insiders
Recent insider trading involved SATO VICKI L, Director, that happened on Jul 01 ’25 when 22000.0 shares were sold. Director, VICKI LEE SATO completed a deal on Jul 01 ’25 to buy 66000.0 shares. Meanwhile, Former Director GEORGE SCANGOS bought 19957.0 shares on Jun 11 ’25.
